Kyverna Therapeutics reports encouraging data for first CAR-T therapy targeting autoimmune disease

Kyverna Therapeutics released new data that strengthens its case for bringing the first CAR‑T treatment for an autoimmune condition to market. The results come after recent safety setbacks in similar programs at Novartis and Bristol Myers Squibb, where three patient deaths and inflammatory events prompted trial pauses.

Novartis has halted several studies of its CAR‑T candidate rap‑cel, and BMS voluntarily froze trials of its zola‑cel asset following serious immune‑related toxicities. These setbacks have raised questions about the suitability of CAR‑T approaches in non‑fatal diseases.

Despite the broader concerns, Kyverna's latest findings suggest a favorable safety and efficacy profile, reigniting analyst interest in the potential of CAR‑T technology for autoimmune disorders. The data may help restore confidence in the therapeutic strategy as the company moves closer to market entry.